Literature DB >> 17311981

Probiotic effects on inflammatory bowel disease.

Barbara Sheil1, Fergus Shanahan, Liam O'Mahony.   

Abstract

Components of the commensal flora, including Bifidobacteria and Lactobacilli, have been associated with beneficial effects on the host. These beneficial effects include maintenance of intestinal homeostasis, competitive exclusion of pathogens, production of antimicrobial compounds, promotion of gut barrier function, and immune modulation. Probiotics currently can be administered in dairy yogurts and drinks and also in the form of sachets or capsules. Although preliminary studies are clearly promising, placebo-controlled, randomized, double-blind clinical trials are required to clarify the role of probiotic bacteria in the treatment of inflammatory bowel disease. The choice of probiotic bacteria, the optimal dose, mode of administration, and duration of therapy still need to be established. Detailed strain characterization is also required for all potential probiotic strains. As evidence accumulates to suggest a breakdown in tolerance toward ubiquitous intestinal bacteria, it appears logical to intervene by modulating the enteric flora. Increasingly, research suggests that probiotics may offer an alternative or adjuvant approach to conventional therapy by altering the intestinal microflora and modulating the host immune system.

Entities:  

Mesh:

Year:  2007        PMID: 17311981     DOI: 10.1093/jn/137.3.819S

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  56 in total

1.  Bifidobacterium lactis attenuates onset of inflammation in a murine model of colitis.

Authors:  David Philippe; Laurent Favre; Francis Foata; Oskar Adolfsson; Genevieve Perruisseau-Carrier; Karine Vidal; Gloria Reuteler; Johanna Dayer-Schneider; Christoph Mueller; Stéphanie Blum
Journal:  World J Gastroenterol       Date:  2011-01-28       Impact factor: 5.742

2.  Anti-inflammatory and immunomodulatory efficacy of indigenous probiotic Lactobacillus plantarum Lp91 in colitis mouse model.

Authors:  Raj Kumar Duary; Mache Amit Bhausaheb; Virender Kumar Batish; Sunita Grover
Journal:  Mol Biol Rep       Date:  2011-09-23       Impact factor: 2.316

Review 3.  Probiotics, prebiotics and synbiotics- a review.

Authors:  Kavita R Pandey; Suresh R Naik; Babu V Vakil
Journal:  J Food Sci Technol       Date:  2015-07-22       Impact factor: 2.701

4.  Immunomodulatory activity of two potential probiotic strains in LPS-stimulated HT-29 cells.

Authors:  Raj Kumar Duary; Virender Kumar Batish; Sunita Grover
Journal:  Genes Nutr       Date:  2014-03-30       Impact factor: 5.523

Review 5.  Therapeutic correction of bacterial dysbiosis discovered by molecular techniques.

Authors:  R Balfour Sartor
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-23       Impact factor: 11.205

6.  Bifidobacterium animalis causes extensive duodenitis and mild colonic inflammation in monoassociated interleukin-10-deficient mice.

Authors:  James P Moran; Jens Walter; Gerald W Tannock; Susan L Tonkonogy; R Balfour Sartor
Journal:  Inflamm Bowel Dis       Date:  2009-07       Impact factor: 5.325

Review 7.  Probiotics in the management of colonic disorders.

Authors:  Eamonn M M Quigley
Journal:  Curr Gastroenterol Rep       Date:  2007-10

8.  Auto-aggregation and co-aggregation ability in bifidobacteria and clostridia.

Authors:  E Vlková; V Rada; M Smehilová; J Killer
Journal:  Folia Microbiol (Praha)       Date:  2008-07-27       Impact factor: 2.099

9.  Lactobacillus plantarum prevents the upregulation of adhesion molecule expression in an experimental colitis model.

Authors:  Zhao-Xin Chu; Hong-Qi Chen; Yan-Lei Ma; Yu-Kun Zhou; Ming Zhang; Peng Zhang; Huan-Long Qin
Journal:  Dig Dis Sci       Date:  2009-12-04       Impact factor: 3.199

10.  Effects of Lactobacillus salivarius 433118 on intestinal inflammation, immunity status and in vitro colon function in two mouse models of inflammatory bowel disease.

Authors:  Linda M Feighery; Philip Smith; Liam O'Mahony; Padraic G Fallon; David J Brayden
Journal:  Dig Dis Sci       Date:  2007-12-20       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.